President Trump May Reschedule Cannabis: Should You Buy MSOS Or NewLake Capital?
Summarize this article with:
Julian LinInvesting Group LeaderFollow5ShareSavePlay(11min)Comment(1)SummaryPresident Trump appears poised to reschedule cannabis to Schedule III.NewLake Capital Partners, Inc. stands to benefit significantly from potential cannabis rescheduling, which could transform tenant cash flows and credit quality.NewLake Capital offers a 12.7% yield, net cash balance sheet, and trades at a steep discount to peers and tenants.I reiterate a strong buy rating on NLCP, viewing it as the best way to capitalize on the regulatory catalyst versus AdvisorShares Pure US Cannabis ETF or operators. Alexander Sanchez/iStock via Getty Images Cannabis stocks are soaring on news that President Trump is looking to reschedule cannabis which would mark a major regulatory milestone for the industry. Most investors appear to be targeting the AdvisorShares Pure US CannabisThis article was written byJulian Lin36.66K FollowersFollowJulian Lin is a financial analyst. He finds undervalued companies with secular growth that appreciate over time. His approach is to look for companies with strong balance sheets and management teams in sectors with long growth runways. Julian is the leader of the investing group Best Of Breed Growth Stocks where he only shares positions in stocks which have a large probability of delivering large alpha relative to the S&P 500. He also combines growth-oriented principles with strict valuation hurdles to add an additional layer to the conventional margin of safety. Features include: exclusive access to Julian's highest conviction picks, full stock research reports, real-time trade alerts, macro market analysis, individual industry reports, a filtered watchlist, and community chat with access to Julian 24/7. Learn more.Analyst’s Disclosure:I/we have a beneficial long position in the shares of NLCP, O, PLD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Recommended For You